Madam Speaker, I acknowledge the member's point that discussion of a formulary is an important discussion to have, but there are great precedents for working toward a common formulary. The common drug review that we had in this country for years served as an expert base. It was a federally run organization that provinces largely deferred to in the composition of their formularies. It was not binding, but it was a structure that was already in place, although some damage was done to that structure in the previous government.
It is a legitimate conversation that has to be had, but there are models for how to come to agreement. The provinces and the federal government did that largely with the CDR process before, and it is something that needs to be done. That is why the motion allows for a year. That time allows all of those people who ought to be at the table to be brought into the discussion. We would not want to make the perfect the enemy of the good.